Executive Summary: Cancer Therapeutics: The Worldwide Market , 2nd Edition

Containing a snapshot of the overall market analysis, each Executive Summary provides a description of the scope and methodology used in the report; a summary of results including market size and market growth; a sampling of charts and graphs when available; and a brief look at the trends shaping the market.

The report from which this Executive Summary is compiled is Cancer Therapeutics: The Worldwide Market, and the full study abstract is as follows:

With over 6,160 individual data points reflecting useful market data, Kalorama's Cancer Therapeutics: The Worldwide Market, 2nd Edition is the most comprehensive and recent information available on the five key cancer therapy and treatment markets in a syndicated market research report, including the following areas:

• Chemotherapy, including
  -Subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives
  -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each
• Hormone Therapy:
  -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS
  -Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron with Market Share for each.
• Radiation Therapy:
  -Radiopharmaceuticals and Radioimmunotherapy categories
  -Products including Bexxar, Theraseed and Zevalin
• Immunotherapy and Biotherapy, including:
  -Monoclonal antibodies, interleukins/interferons, vaccines and other biotherapy
  -Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux
• Adjunctive Therapies, including:
  -Antinauseants, Antiemetics, Pain Management Drugs and Biological Response Modifiers.

Few pharmaceutical markets will see the dramatic change that will occur in the market for cancer treatments over the next four years. More than $8 billion dollars worth of new products are expected in the next four years, impacting the treatment of cancer in ways that product managers, strategic planners, business development managers and marketing executives will need to be aware of.

Between 2004 and 2006, the market for cancer therapeutics saw more than an 18% increase, presaging future growth. Given the promising therapy pipeline and increasing incidence of cancer, double-digit growth is expected annually, leading to opportunities for current players and new entrants alike.